These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
508 related articles for article (PubMed ID: 16126760)
1. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Hedmer M; Georgiadi A; Bremberg ER; Jönsson BA; Eksborg S Ann Occup Hyg; 2005 Oct; 49(7):629-37. PubMed ID: 16126760 [TBL] [Abstract][Full Text] [Related]
2. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Crauste-Manciet S; Sessink PJ; Ferrari S; Jomier JY; Brossard D Ann Occup Hyg; 2005 Oct; 49(7):619-28. PubMed ID: 16126757 [TBL] [Abstract][Full Text] [Related]
3. Hygienic guidance values for wipe sampling of antineoplastic drugs in Swedish hospitals. Hedmer M; Wohlfart G J Environ Monit; 2012 Jul; 14(7):1968-75. PubMed ID: 22692549 [TBL] [Abstract][Full Text] [Related]
4. Development and validation of methods for environmental monitoring of cyclophosphamide in workplaces. Hedmer M; Jönsson BA; Nygren O J Environ Monit; 2004 Dec; 6(12):979-84. PubMed ID: 15568047 [TBL] [Abstract][Full Text] [Related]
5. A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Acampora A; Castiglia L; Miraglia N; Pieri M; Soave C; Liotti F; Sannolo N Ann Occup Hyg; 2005 Oct; 49(7):611-8. PubMed ID: 15964876 [TBL] [Abstract][Full Text] [Related]
6. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Hedmer M; Tinnerberg H; Axmon A; Jönsson BA Int Arch Occup Environ Health; 2008 Jul; 81(7):899-911. PubMed ID: 18066576 [TBL] [Abstract][Full Text] [Related]
7. Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning. Chu WC; Hon CY; Danyluk Q; Chua PP; Astrakianakis G J Oncol Pharm Pract; 2012 Mar; 18(1):46-51. PubMed ID: 21737485 [TBL] [Abstract][Full Text] [Related]
8. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device. Siderov J; Kirsa S; McLauchlan R J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949 [TBL] [Abstract][Full Text] [Related]
9. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Minoia C; Turci R; Sottani C; Schiavi A; Perbellini L; Angeleri S; Draicchio F; Apostoli P Rapid Commun Mass Spectrom; 1998; 12(20):1485-93. PubMed ID: 9796535 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of surface contamination in a hospital hematology--oncology pharmacy. Touzin K; Bussières JF; Langlois E; Lefebvre M J Oncol Pharm Pract; 2009 Mar; 15(1):53-61. PubMed ID: 18772214 [TBL] [Abstract][Full Text] [Related]
12. Association of surface contamination by antineoplastic drugs with different working conditions in hospital pharmacies. Odraska P; Dolezalova L; Kuta J; Oravec M; Piler P; Synek S; Blaha L Arch Environ Occup Health; 2014; 69(3):148-58. PubMed ID: 24325745 [TBL] [Abstract][Full Text] [Related]
13. [Antiblastic drug exposure: statistical analysis of the data coming from environmental monitoring of a site devoted to drug production]. Miraglia N; Castiglia L; Muselli A; Astarita S; Acampora A; Sannolo N G Ital Med Lav Ergon; 2007; 29(3 Suppl):739-40. PubMed ID: 18409934 [TBL] [Abstract][Full Text] [Related]
14. Environmental contamination with methotrexate in Canadian community pharmacies. Merger D; Tanguay C; Langlois É; Lefebvre M; Bussières JF J Am Pharm Assoc (2003); 2013; 53(4):423-6. PubMed ID: 23892817 [TBL] [Abstract][Full Text] [Related]
15. Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals. Hon CY; Teschke K; Chu W; Demers P; Venners S J Occup Environ Hyg; 2013; 10(7):374-83. PubMed ID: 23668810 [TBL] [Abstract][Full Text] [Related]
16. Contamination of syringe plungers during the sampling of cyclophosphamide solutions. Favier B; Gilles L; Latour JF; Desage M; Giammarile F J Oncol Pharm Pract; 2005 Mar; 11(1):1-5. PubMed ID: 16460597 [TBL] [Abstract][Full Text] [Related]
17. Verification of surface contamination of Japanese cyclophosphamide vials and an example of exposure by handling. Hama K; Fukushima K; Hirabatake M; Hashida T; Kataoka K J Oncol Pharm Pract; 2012 Jun; 18(2):201-6. PubMed ID: 21947739 [TBL] [Abstract][Full Text] [Related]
18. Occupational exposure to antineoplastic drugs in hospital environments: potential risk associated with contact with cyclophosphamide- and ifosfamide-contaminated surfaces. Mucci N; Dugheri S; Farioli A; Garzaro G; Rapisarda V; Campagna M; Bonari A; Arcangeli G Med Pr; 2020 Sep; 71(5):519-529. PubMed ID: 32667290 [TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide contamination observed on the external surfaces of drug vials and the efficacy of cleaning on vial contamination. Touzin K; Bussières JF; Langlois E; Lefebvre M; Gallant C Ann Occup Hyg; 2008 Nov; 52(8):765-71. PubMed ID: 18663228 [TBL] [Abstract][Full Text] [Related]
20. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Sessink PJ; Boer KA; Scheefhals AP; Anzion RB; Bos RP Int Arch Occup Environ Health; 1992; 64(2):105-12. PubMed ID: 1399019 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]